Polymporphism of monocyte chemoattractant protein 1 (MCP1 -2518 A/G) and responsiveness to hepatitis B vaccination in hemodialysis patients

Polskie Archiwum Medycyny Wewnetrznej

Volumn 124, Issue 1-2, 2014, Pages 10-18

  Grzegorzewska, Alicja E ^a   Pajzderski, Dominik ^a   Sowińska, Anna ^a   Jagodziński, Paweł P ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Diabetes; Hemodialysis; Hepatitis B vaccination; MCP1 2518 A G rs1024611; Monocyte chemoattractant protein 1

Indexed keywords

ALANINE; GLYCINE; HEPATITIS B ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT HEPATITIS B VACCINE; BIOLOGICAL MARKER; HEPATITIS B VACCINE;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; END STAGE RENAL DISEASE; FEMALE; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT RESPONSE; VACCINATION; VERY ELDERLY; BLOOD; COMPARATIVE STUDY; COMPLICATION; CONTROLLED CLINICAL TRIAL; GENETIC POLYMORPHISM; GENETICS; KIDNEY DISEASES; RENAL REPLACEMENT THERAPY;

AGED; AGED, 80 AND OVER; BIOMARKERS; CHEMOKINE CCL2; DIABETES MELLITUS; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RENAL DIALYSIS; VACCINATION;

EID: 84894212568     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.2069     Document Type: Article

References (58)

1. Murea M, Register TC, Divers J, et al. Relationships between serum MCP-1 and subclinical kidney disease: African American-Diabetes Heart Study. BMC Nephrol. 2012; 3: 148.
2. Suzuki E, Karam E, Williams S, et al. Fli-1 transcription factor affects glomerulonephritis development by regulating expression of monocyte chemoattractant protein-1 in endothelial cells in the kidney. Clin Immunol. 2012; 145: 201-208.
3. Ellina O, Chatzigeorgiou A, Kouyanou S, et al. Extracellular matrix-associated (GAGs, CTGF), angiogenic (VEGF) and inflammatory factors (MCP-1, CD40, IFN-γ) in type 1 diabetes mellitus nephropathy. Clin Chem Lab Med. 2012; 50: 167-174.
4. Uchida E, Anan F, Masaki T, et al. Monocyte chemoattractant protein-1 is associated with silent cerebral infarction in patients on haemodialysis. Intern Med J. 2012; 42: 29-34.
5. Morena M, Jaussent I, Chalabi L, et al. Biocompatibility of heparin-grafted hemodialysis membranes: impact on monocyte chemoattractant protein-1 circulating level and oxidative status. Hemodial Int. 2010; 14: 403-410.
6. Olsson J, Paulsson J, Dadfar E, et al. Monocyte and neutrophil chemotactic activity at the site of interstitial inflammation in patients on high-flux hemodialysis or hemodiafiltration. Blood Purif. 2009; 28: 47-52.
7. Buraczyńska M, Bednarek-Skublewska A, Buraczyńska K, et al. Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism as a potential risk factor for cardiovascular disease in hemodialyzed patients. Cytokine. 2008; 44: 361-365.
8. Papayianni A, Alexopoulos E, Giamalis P, et al. Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events. Nephrol Dial Transplant. 2002; 17: 435-441.
9. Meng ZF, Wang HJ, Yao X, et al. Immunization with HBsAg-Fc fusion protein induces a predominant production of Th1 cytokines and reduces HBsAg level in transgenic mice. Chin Med J (Engl). 2012; 125: 3266-3272.
10. Fierro NA, Roman S, Realpe M, et al. Multiple cytokine expression profiles reveal immune-based differences in occult hepatitis B genotype H-infected Mexican Nahua patients. Mem Inst Oswaldo Cruz. 2011; 106: 1007-1013.
11. Grzegorzewska AE, Kaczmarek-Leki V, Młot-Michalska M, Niepolski L. Seroconversion rate to positivity for antibodies against core antigen of hepatitis B virus and duration of renal replacement therapy. Nephrol Dial Transplant. 2011; 26: 970-976.
12. Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun. 1999; 259: 344-348.
13. Fenoglio C, Galimberti D, Lovati C, et al. MCP-1 in Alzheimer's disease patients: A -2518G polymorphism and serum levels. Neurobiol Aging. 2004; 25: 1169-1173.
14. Omori K, Kazama JJ, Song J, et al. Association of the MCP-1 gene polymorphism A-2518G with carpal-tunnel syndrome in hemodialysis patients. Amyloid. 2002; 9: 175-182.
15. Park BL, Kim YJ, Cheong HS, et al. Association of common promoter polymorphisms of MCP1 with hepatitis B virus clearance. Exp Mol Med. 2006; 38: 694-702.
16. Cheong JY, Cho SW, Choi JY, et al. RANTES, MCP-1, CCR2, CCR5, CXCR1 and CXCR4 gene polymorphisms are not associated with the outcome of hepatitis B virus infection: results from a large scale single ethnic population. J Korean Med Sci. 2007; 22: 529-535.
17. Polakowska M, Piotrowski W. Incidence of diabetes in the Polish population: results of the Multicenter Polish Population Health Status Study -WOBASZ. Pol Arch Med Wewn. 2011; 121: 156-163.
18. Sattar A, Argyropoulos C, Weissfeld L, et al. All-cause and cause-specific mortality associated with diabetes in prevalent hemodialysis patients. BMC Nephrol. 2012; 13: 130.
19. Karadeniz M, Erdogan M, Cetinkalp S, et al. Monocyte chemoattractant protein-1 (MCP-1) 2518G/A gene polymorphism in Turkish type 2 diabetes patients with nephropathy. Endocrine. 2010; 37: 513-517.
20. Simeoni E, Hoffmann MM, Winkelmann BR, et al. Association between the A-2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and Type 2 diabetes mellitus. Diabetologia. 2004; 47: 1574-1580.
21. Yang B, Houlberg K, Millward A, Demaine A. Polymorphisms of chemokine and chemokine receptor genes in Type 1 diabetes mellitus and its complications. Cytokine. 2004, 26: 114-121.
22. Zhang Y, Zhang J, Tian C, et al. The -2518A/G polymorphism in the monocyte chemoattractant protein-1 (MCP-1) gene and diabetes risk: a meta-analysis. Diabetes Res Clin Pract. 2011; 94: e89-92.
23. Alavian SM, Tabatabaei SV. The effect of diabetes mellitus on immunological response to hepatitis B virus vaccine in individuals with chronic kidney disease: A meta-analysis of current literature. Vaccine. 2010; 28: 3773-3777.
24. Grzegorzewska AE, Ratajewska A, Wiesiołowska A. Echocardiographic indices in hemodialysis patients in a six-month observation. Adv Clin Exp Med. 2011; 20: 431-440.
25. Ratajewska A, Grzegorzewska AE, Wiesiołowska A. [Dilatation of the left atrium as one of the indicators of worse prognosis in patients treated with intermittent hemodialysis]. Pol Merkur Lekarski. 2012; 33: 64-69. Polish.
26. Mostowska M, Lianeri M, Oko A, et al. No association of monocyte chemoattractant protein-1 22 518 A/G polymorphism with the risk of primary glomerulonephritis in the Polish population. Mol Biol Rep. 2012; 39: 5933-5941.
27. PS: Power and Sample Size Calculation http://biostat.mc.vanderbilt.edu/ twiki/bin/view/main/powersamplesize. Accessed August, 2013.
28. Venkat-Raman G, Tomson CR, Gao Y, et al. New primary renal diagnosis codes for the ERA-EDTA. Nephrol Dial Transplant. 2012; 27: 4414-4419.
29. Grzegorzewska AE, Wobszal P, Mostowska A, et al. Antibodies to hepatitis B virus surface antigen and interleukin 12 and interleukin 18 gene polymorphisms in hemodialysis patients. BMC Nephrol. 2012; 13: 75.
30. Grzegorzewska AE, Wobszal P, Jagodzinski PP. Interleukin-18 promoter polymorphism and development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients. Kidney Blood Press Res. 2012; 35: 1-8.
31. Grzegorzewska AE, Pajzderski D, Sowińska A, et al. IL4R and IL13 polymorphic variants and development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients in response to HBV vaccination or infection. Vaccine. 2013; 31: 1766-1770.
32. Lin YJ, Lan YC, Huang YC, et al. Effects of cytokine and cytokine receptor gene variation on high anti-HB titers: following up on Taiwan's neonatal hepatitis B immunization program. Clin Chim Acta. 2012; 413: 1194-1198.
33. Lin YJ, Lan YC, Wan L, et al. Serological surveillance and IL-10 genetic variants on anti-HBs titers: hepatitis B vaccination 20 years after neonatal immunization in Taiwan. Clin Chim Acta. 2011; 412: 766-773.
34. Wang C, Tang J, Song W, et al. HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination. Hepatology. 2004; 39: 978-988.
35. Girndt M, Sester U, Sester M, et al. The interleukin-10 promoter genotype determines clinical immune function in hemodialysis patients. Kidney Int. 2001; 60: 2385-2391.
36. Höhler T, Reuss E, Freitag CM, Schneider PM. A functional polymorphism in the IL-10 promoter influences the response after vaccination with HBsAg and hepatitis A. Hepatology. 2005; 42: 72-76.
37. Yucesoy B, Sleijffers A, Kashon M, et al. IL-1beta gene polymorphisms influence hepatitis B vaccination. Vaccine. 2002; 20: 3193-3196.
38. Chen J, Liang Z, Lu F, et al. Toll-like receptors and cytokines/cytokine receptors polymorphisms associate with non-response to hepatitis B vaccine. Vaccine. 2011; 29: 706-711.
39. Sleijffers A, Yucesoy B, Kashon M, et al. Cytokine polymorphisms play a role in susceptibility to ultraviolet B-induced modulation of immune responses after hepatitis B vaccination. J Immunol. 2003; 170: 3423-3428.
40. Hennig BJ, Fielding K, Broxholme J, et al. Host genetic factors and vaccine-induced immunity to hepatitis B virus infection. PLoS One. 2008; 3: e1898.
41. Flex A, Gaetani E, Papaleo P, et al. Proinflammatory genetic profiles in subjects with history of ischemic stroke. Stroke. 2004; 35: 2270-2275.
42. Ben-Selma W, Harizi H, Boukadida J. MCP-1 -2518 A/G functional polymorphism is associated with increased susceptibility to active pulmonary tuberculosis in Tunisian patients. Mol Biol Rep. 2011; 38: 5413-5419.
43. Flores-Villanueva PO, Ruiz-Morales JA, Song CH, et al. A functional promoter polymorphism in monocyte chemoattractant protein-1 is associated with increased susceptibility to pulmonary tuberculosis. J Exp Med. 2005; 202: 1649-1658.
44. Möller M, Nebel A, Valentonyte R, et al. Investigation of chromosome 17 candidate genes in susceptibility to TB in a South African population. Tuberculosis (Edinb). 2009; 89: 189-194.
45. Szalai C, Duba J, Prohászka Z, et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis. 2001; 158: 233-239.
46. Xu ZE, Xie YY, Chen JH, et al. [Monocyte chemotactic protein-1 gene polymorphism and monocyte chemotactic protein-1 expression in Chongqing Han children with tuberculosis]. Zhonghua Er Ke Za Zhi. 2009; 47: 200-203. Chinese.
47. Nahar K, Jahan M, Nessa A, Tabassum S. Antibody responses after hepatitis B vaccination among maintenance haemodialysis patients. Bangladesh Med Res Counc Bull. 2011; 37: 88-91.
48. Mitchell LA, Henderson AJ, Dow SW. Suppression of vaccine immunity by inflammatory monocytes. J Immunol. 2012; 189: 5612-5621.
49. Lin HL, Ueng KC, Hsieh YS, et al. Impact of MCP-1 and CCR-2 gene polymorphisms on coronary artery disease susceptibility. Mol Biol Rep. 2012; 39: 9023-9030.
50. El Mahgoub IR, Afify RA, Aal AA, Beda DG. Association between the monocyte chemoattractant protein-1 -2518G/A gene polymorphism and acute myocardial infarction patients among Egyptian population. Blood Coagul Fibrinolysis. 2011; 22: 7-13.
51. Mori H, Kaneko Y, Narita I, et al. Monocyte chemoattractant protein-1 A-2518G gene polymorphism and renal survival of Japanese patients with immunoglobulin A nephropathy. Clin Exp Nephrol. 2005; 9: 297-303.
52. Kaur S, Panicker SR, James T, et al. Association of monocyte chemoattractant protein-1 -2518 polymorphism with metabolic syndrome in a South Indian cohort. Metab Syndr Relat Disord. 2009; 7: 193-198.
53. Zhong C, Luzhan Z, Genshan M, et al. Monocyte chemoattractant protein-1-2518 G/A polymorphism, plasma levels, and premature stable coronary artery disease. Mol Biol Rep. 2010; 37: 7-12.
54. Cermakova Z, Petrkova J, Arakelyan A, et al. The MCP-1 -2518 (A to G) single nucleotide polymorphism is not associated with myocardial infarction in the Czech population. Int J Immunogenet. 2005; 32: 315-318.
55. Zhang Y, Zhang J, Zeng L, et al. The -2518A/G polymorphism in the MCP-1 gene and tuberculosis risk: a meta-analysis. PLoS One. 2012; 7: e38 918.
56. Tucci M, Barnes EV, Sobel ES, et al. Strong association of a functional polymorphism in the monocyte chemoattractant protein 1 promoter gene with lupus nephritis. Arthritis Rheum. 2004; 50: 1842-1849.
57. Wang L, Yang L, Gao L, et al. A functional promoter polymorphism in monocyte chemoattractant protein-1 is associated with psoriasis. Int J Immunogenet. 2008; 35: 45-49.
58. Jemaa R, Ben Ali S, Kallel A, et al. Association between the -2518G/A polymorphism in the monocyte chemoattractant protein-1 (MCP-1) gene and hypertension in Tunisian patients. Clin Biochem. 2009; 42: 34-37.